<DOC>
	<DOCNO>NCT01410162</DOCNO>
	<brief_summary>Renal kidney pancreas transplant patient randomize daily Advagraf twice daily Prograf ass change tacrolimus mycophenolate mofetil exposure , renal allograft function , relevant biochemical parameter treatment related adverse effect .</brief_summary>
	<brief_title>Advagraf/Prograf Conversion Trial</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Renal transplant Renal Pancreas patient &gt; 12 month post transplant Stable allograft function define eGFR &gt; 3060ml/min Renal patient stable tacrolimus trough level 58ng/ml prior 3 month ; Renal pancreas patient stable tacrolimus trough level 310 mg/ml prior 3 month Receiving concomitant therapy mycophenolate mofetil dose 5001000mg bid equivalent Any surgical medical condition , opinion investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Treated rejection within 3 month randomization . Increased serum creatinine &gt; 20 % within 3 month randomization . Subject pregnant breastfeeding Subject significant comorbid disease ( eg . Malignancy uncontrolled infection ) disability ( e.g . cognitive deficit ) prevent understanding , adherence , protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Renal</keyword>
	<keyword>Kidney/Pancreas</keyword>
	<keyword>Transplant</keyword>
	<keyword>conversion</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>Mycophenolate Acid</keyword>
</DOC>